BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin

Authors:
Eric J RoelandMassachusetts General Hospital, Boston, MA

Search for other papers by Eric J Roeland in
Current site
Google Scholar
PubMed
Close
 MD
,
Thomas W. LeBlancDuke University School of Medicine, Duke Cancer Institute, Durham, NC

Search for other papers by Thomas W. LeBlanc in
Current site
Google Scholar
PubMed
Close
 MD, MA, MHS
,
Kathryn J. RuddyMayo Clinic, Rochester, MN

Search for other papers by Kathryn J. Ruddy in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Ryan NippMassachusetts General Hospital, Boston, MA

Search for other papers by Ryan Nipp in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Rebecca Clark-SnowOncology Supportive Care Consultant, Overland Park, KS

Search for other papers by Rebecca Clark-Snow in
Current site
Google Scholar
PubMed
Close
 RN, BSN, OCN
,
Rita WickhamRush University College of Nursing, Chicago, IL

Search for other papers by Rita Wickham in
Current site
Google Scholar
PubMed
Close
 PhD, RN, AOCN
,
Gary BinderHelsinn Therapeutics US, Iselin, NJ

Search for other papers by Gary Binder in
Current site
Google Scholar
PubMed
Close
 MBA
,
William L. BaileyHelsinn Therapeutics US, Iselin, NJ

Search for other papers by William L. Bailey in
Current site
Google Scholar
PubMed
Close
 PharmD
,
Ravi PotluriSmartAnalyst, Inc., New York, NY

Search for other papers by Ravi Potluri in
Current site
Google Scholar
PubMed
Close
 MBA
,
Luke M. SchmeroldSmartAnalyst, Inc., New York, NY

Search for other papers by Luke M. Schmerold in
Current site
Google Scholar
PubMed
Close
 BS
,
Eros PapademetriouSmartAnalyst, Inc., New York, NY

Search for other papers by Eros Papademetriou in
Current site
Google Scholar
PubMed
Close
 MS
, and
Rudolph M. NavariUniversity of Alabama Birmingham School of Medicine, Birmingham, AL

Search for other papers by Rudolph M. Navari in
Current site
Google Scholar
PubMed
Close
 MD, PhD

Background: Avoiding acute care services can improve cancer care and reduce cost. The US Centers for Medicare and Medicaid Services’ (CMS) new oncology outcome measure (OP-35) defines 30-day post-chemotherapy inpatient (IP) and/or emergency department (ED) events (IP/ED) as “potentially avoidable” if involving any of 10 toxicities, including nausea or vomiting (NV). Evidence demonstrates meaningful gaps in oncologists’ adherence to antiemetic prophylaxis guidelines for highly emetogenic chemotherapy (HEC), and that NV-related IP use costs >$10,000; yet the incidence of avoidable acute care events involving NV is not well studied. Methods: We assessed chemotherapy courses using IBM Explorys electronic health records (4Q 2012–1Q 2018). We identified rates of IP/ED ≤30 days post-chemotherapy, and OP-35 toxicities (NV, anemia, dehydration, diarrhea, fever, neutropenia, pain, pneumonia, or sepsis) by ICD-9, ICD-10, procedure codes, and CMS criteria. We evaluated cisplatin, anthracycline + cyclophosphamide (AC), carboplatin (>14 days apart, as a proxy for AUC ≥4), oxaliplatin (OX), and other non-HEC chemotherapy. We assessed guideline adherence, defined as triple prophylaxis (NK1 RA + 5HT3 RA +dexamethasone) rates at HEC initiation. Results: In 17,609 HEC and 56,624 non-HEC courses, we observed 30-day IP/ED utilization in 29% and 19% of courses, respectively (). For HEC, 76% of IP/ED use involved ≥1 of the 10 CMS toxicities, most often anemia (42%), pain (41%), dehydration (24%), and NV (24%). Rates of all-cause IP/ED, IP/ED with OP-35 toxicity, and NV-related IP/ED were consistent for HEC and OX. Gaps in triple prophylaxis were common in HEC. Conclusion: Roughly one-third of patients receiving HEC or OX experienced IP/ED events ≤30 days after chemotherapy. Three-quarters of IP/ED events involved ≥1 of 10 OP-35 toxicities linked by CMS to potentially avoidable acute care; of these, one-third involved NV. NV-associated acute care use is considerable, costly, and potentially avoidable with better adherence to antiemesis guidelines.

Background: Avoiding acute care services can improve cancer care and reduce cost. The US Centers for Medicare and Medicaid Services’ (CMS) new oncology outcome measure (OP-35) defines 30-day post-chemotherapy inpatient (IP) and/or emergency department (ED) events (IP/ED) as “potentially avoidable” if involving any of 10 toxicities, including nausea or vomiting (NV). Evidence demonstrates meaningful gaps in oncologists’ adherence to antiemetic prophylaxis guidelines for highly emetogenic chemotherapy (HEC), and that NV-related IP use costs >$10,000; yet the incidence of avoidable acute care events involving NV is not well studied. Methods: We assessed chemotherapy courses using IBM Explorys electronic health records (4Q 2012–1Q 2018). We identified rates of IP/ED ≤30 days post-chemotherapy, and OP-35 toxicities (NV, anemia, dehydration, diarrhea, fever, neutropenia, pain, pneumonia, or sepsis) by ICD-9, ICD-10, procedure codes, and CMS criteria. We evaluated cisplatin, anthracycline + cyclophosphamide (AC), carboplatin (>14 days apart, as a proxy for AUC ≥4), oxaliplatin (OX), and other non-HEC chemotherapy. We assessed guideline adherence, defined as triple prophylaxis (NK1 RA + 5HT3 RA +dexamethasone) rates at HEC initiation. Results: In 17,609 HEC and 56,624 non-HEC courses, we observed 30-day IP/ED utilization in 29% and 19% of courses, respectively (Table 1). For HEC, 76% of IP/ED use involved ≥1 of the 10 CMS toxicities, most often anemia (42%), pain (41%), dehydration (24%), and NV (24%). Rates of all-cause IP/ED, IP/ED with OP-35 toxicity, and NV-related IP/ED were consistent for HEC and OX. Gaps in triple prophylaxis were common in HEC. Conclusion: Roughly one-third of patients receiving HEC or OX experienced IP/ED events ≤30 days after chemotherapy. Three-quarters of IP/ED events involved ≥1 of 10 OP-35 toxicities linked by CMS to potentially avoidable acute care; of these, one-third involved NV. NV-associated acute care use is considerable, costly, and potentially avoidable with better adherence to antiemesis guidelines.

T1

Corresponding Author: Eric Roeland, MD
  • Collapse
  • Expand